HUMAN VACCINE RESEARCH
ALLOY IS OUR ALLY
We exist to create vaccines so people can enjoy life more fully
Antibiotics were the single most important medical advance of the 1900s, but almost immediately, resistant bacteria emerged and have continued to spread. In contrast, vaccines provide lasting protection against bacteria without the risk of resistance.
URINARY TRACT INFECTIONS
Urinary tract infections (UTI) are responsible for more antimicrobial use globally than any other human disease. A vaccine to prevent UTI would greatly reduce the use of antimicrobials, which will extend their usefulness to protect against other infections.
ALLOY VACCINE PLATFORM
Syntiron’s ALLOY Vaccine Platform targets multiple bacterial iron receptors to generate vaccines that are strong, broadly protective and easy to make. Syntiron’s first ALLOY Vaccine targets UTI. ALLOY is our ALLY against antimicrobial resistant bacteria.
CARB-X IS FUNDING SYNTIRON
CARB-X IS FUNDING SYNTIRON TO DEVELOP A MATERNAL VACCINE TO PREVENT NEONATAL SEPSIS
“CARB-X is excited to support the development of Syntiron’s maternal vaccine to help prevent neonatal sepsis, the leading cause of death among infants, especially those located in low- and middle-income countries …”
ANTIMICROBIAL RESISTANCE IMPACTS ALL OF US
A GROWING GLOBAL PANDEMIC
- Common diseases are becoming untreatable and lifesaving medical procedures are riskier to perform due to AMR.
- 35-90% of infections are due to resistant bacteria worldwide.
- AMR infections are projected to surpass cancer as a leading cause of death worldwide (>10M) by 2050.
- The impact on the global gross domestic product is estimated at 100 trillion USD by 2050.
AMR vaccines are needed
- Vaccine development for bacteria was deprioritized after the discovery of antibiotics, so relatively few bacterial vaccines are currently available.
- Long term, vaccines are the most reliable and economically feasible option to address AMR.
- Syntiron’s ALLOY Platform can be used to develop the AMR vaccines that are needed to save lives in every age group throughout the planet, starting with UTI.
UTI vaccine: an AMR priority
- Urinary tract infections result in more antimicrobial use globally than any other disease.
- UTIs are becoming more difficult to treat due to AMR.
- At least 30% of people will experience UTI at least once during their lifetime.
- A UTI vaccine will dramatically reduce antimicrobial use and protect against serious invasive infections caused by untreatable AMR bacteria.
Syntiron’s Alloy Vaccine Platform targets multiple bacterial metal transport proteins to generate synthetic protein vaccines that are strong, broadly protective, and easy to make.
The superior strength of steel comes from the combination of iron and carbon. Steel is an alloy: a metal that is stronger than its individual parts.
Syntiron’s ALLOY Vaccine Platform leverages the same principal to combine multiple bacterial components, especially metal receptors, to enhance strength and durability. The resulting ALLOY vaccines are simple to manufacture, induce multiple arms of immunity and target a broad range of bacteria strains. The ALLOY Vaccine Platform is our ALLY against AMR.
“It makes good scientific sense to make a vaccine against [bacterial] proteins that bond with iron.”
Dr. Gregory Poland, M.D., Director of Mayo Clinical Vaccine Research Group
1000 Westgate Drive
St Paul MN 55114